Luke Evnin - Net Worth and Insider Trading

Luke Evnin Net Worth

The estimated net worth of Luke Evnin is at least $35 Million dollars as of 2024-04-25. Luke Evnin is the Director of Pacira BioSciences Inc and owns about 824,255 shares of Pacira BioSciences Inc (PCRX) stock worth over $21 Million. Luke Evnin is the Director, 10% Owner of Harpoon Therapeutics Inc and owns about 452,443 shares of Harpoon Therapeutics Inc (HARP) stock worth over $10 Million. Luke Evnin is also the 10% Owner of Rigel Pharmaceuticals Inc and owns about 1,687,072 shares of Rigel Pharmaceuticals Inc (RIGL) stock worth over $2 Million. Besides these, Luke Evnin also holds Conatus Pharmaceuticals Inc (CNAT) , Oncorus Inc (ONCR) . Details can be seen in Luke Evnin's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Luke Evnin has not made any transactions after 2020-10-06 and currently still holds the listed stock(s).

Transaction Summary of Luke Evnin

To

Luke Evnin Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Luke Evnin owns 35 companies in total, including Turmeric Acquisition Corp () , Oncorus Inc () , and Dyne Therapeutics Inc () among others .

Click here to see the complete history of Luke Evnin’s form 4 insider trades.

Insider Ownership Summary of Luke Evnin

Ticker Comapny Transaction Date Type of Owner
Turmeric Acquisition Corp 2020-10-15 Chief Executive Officer
Oncorus Inc 2020-10-06 director & 10 percent owner
Dyne Therapeutics Inc 2020-09-16 10 percent owner
ITeos Therapeutics Inc 2020-07-23 10 percent owner
Repare Therapeutics Inc 2020-06-18 10 percent owner
Harpoon Therapeutics Inc 2019-02-12 director & 10 percent owner
TCR2 Therapeutics Inc 2019-02-13 10 percent owner
Syndax Pharmaceuticals Inc 2016-03-02 director & 10 percent owner
Rhythm Pharmaceuticals Inc 2017-10-04 10 percent owner
Radius Health Inc 2008-06-15 10 percent owner
Avalo Therapeutics Inc 2015-10-14 10 percent owner
Chiasma Inc 2015-07-21 10 percent owner
Reshape Lifesciences Inc 2014-05-07 director
TriVascular Technologies Inc 2014-04-22 10 percent owner
Aratana Therapeutics Inc 2014-03-10 10 percent owner
Epizyme Inc 2013-05-30 10 percent owner
Histogen Inc 2013-07-24 10 percent owner
Pacira BioSciences Inc 2013-06-13 director & 10 percent owner
Humanigen Inc 2012-08-11 10 percent owner
Verastem Inc 2012-01-26 other: Former 10% stockholder
EPIRUS Biopharmaceuticals Inc 2011-10-27 10 percent owner
Altimmune Inc 2007-08-03 other: See explanation below
ARYx Therapeutics Inc 2010-09-30 10 percent owner
AVEO Pharmaceuticals Inc 2010-03-11 10 percent owner
Metabasis Therapeutics Inc 2010-01-27 director & 10 percent owner
Poniard Pharmaceuticals Inc 2009-11-05 10 percent owner
T-Mobile US Inc 2004-07-28 10 percent owner
Affymax Inc 2006-12-19 10 percent owner
Acorda Therapeutics Inc 2003-12-17 10 percent owner
Rigel Pharmaceuticals Inc 2004-09-01 10 percent owner
Cyclacel Pharmaceuticals Inc 2004-03-10 10 percent owner
iPass Inc 2004-02-09 10 percent owner
Entrada Therapeutics Inc 2021-10-28 10 percent owner
Werewolf Therapeutics Inc 2022-06-01 director
Turmeric Acquisition Corp 2020-10-15 Chief Executive Officer

Luke Evnin Latest Holdings Summary

Luke Evnin currently owns a total of 5 stocks. Among these stocks, Luke Evnin owns 824,255 shares of Pacira BioSciences Inc (PCRX) as of June 13, 2013, with a value of $21 Million and a weighting of 61.63%. Luke Evnin owns 452,443 shares of Harpoon Therapeutics Inc (HARP) as of February 12, 2019, with a value of $10 Million and a weighting of 30.06%. Luke Evnin also owns 1,687,072 shares of Rigel Pharmaceuticals Inc (RIGL) as of September 1, 2004, with a value of $2 Million and a weighting of 5.48%. The other 2 stocks Conatus Pharmaceuticals Inc (CNAT) , Oncorus Inc (ONCR) have a combined weighting of 2.83% among all his current holdings.

Latest Holdings of Luke Evnin

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PCRX Pacira BioSciences Inc 2013-06-13 824,255 25.90 21,348,205
HARP Harpoon Therapeutics Inc 2019-02-12 452,443 23.01 10,410,713
RIGL Rigel Pharmaceuticals Inc 2004-09-01 1,687,072 1.13 1,897,956
CNAT Conatus Pharmaceuticals Inc 2013-07-30 1,192,080 0.56 667,565
ONCR Oncorus Inc 2020-10-06 2,492,843 0.13 314,098

Holding Weightings of Luke Evnin


Luke Evnin Form 4 Trading Tracker

According to the SEC Form 4 filings, Luke Evnin has made a total of 0 transactions in Pacira BioSciences Inc (PCRX) over the past 5 years. The most-recent trade in Pacira BioSciences Inc is the sale of 22,746 shares on June 13, 2013, which brought Luke Evnin around $683,972.

According to the SEC Form 4 filings, Luke Evnin has made a total of 0 transactions in Harpoon Therapeutics Inc (HARP) over the past 5 years. The most-recent trade in Harpoon Therapeutics Inc is the acquisition of 25,000 shares on February 12, 2019, which cost Luke Evnin around $4 Million.

According to the SEC Form 4 filings, Luke Evnin has made a total of 0 transactions in Rigel Pharmaceuticals Inc (RIGL) over the past 5 years. The most-recent trade in Rigel Pharmaceuticals Inc is the sale of 85,853 shares on September 1, 2004, which brought Luke Evnin around $2 Million.

More details on Luke Evnin's insider transactions can be found in the Insider Trading History of Luke Evnin table.

Insider Trading History of Luke Evnin

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Luke Evnin Trading Performance

GuruFocus tracks the stock performance after each of Luke Evnin's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Luke Evnin is 32.21%. GuruFocus also compares Luke Evnin's trading performance to market benchmark return within the same time period. The performance of stocks bought by Luke Evnin within 3 months outperforms 3 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Luke Evnin's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Luke Evnin

Average Return

37.17%

Average return per transaction

Outperforming Transactions

67%

4 out of 6 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 5.24 32.21 19.06 37.17 50.69 34.74
Relative Return to S&P 500(%) 3.87 25.97 13.84 20.39 36.99 21.34

Luke Evnin Ownership Network

Ownership Network List of Luke Evnin

No Data

Ownership Network Relation of Luke Evnin


Luke Evnin Owned Company Details

What does Turmeric Acquisition Corp do?

Who are the key executives at Turmeric Acquisition Corp?

Luke Evnin is the Chief Executive Officer of Turmeric Acquisition Corp. Other key executives at Turmeric Acquisition Corp include Chief Financial Officer Edward Hurwitz , President Todd Foley , and 10 percent owner Turmeric Management, Llc .

Turmeric Acquisition Corp () Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Turmeric Acquisition Corp () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Turmeric Acquisition Corp () were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Turmeric Acquisition Corp ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Turmeric Acquisition Corp Insider Transactions

No Available Data

Luke Evnin Mailing Address

Above is the net worth, insider trading, and ownership report for Luke Evnin. You might contact Luke Evnin via mailing address: The John Hancock Tower, 200 Clarendon Street, 54th Street, Boston Ma 02116.

Discussions on Luke Evnin

No discussions yet.